Our News Library | Levin Papantonio Rafferty - Personal Injury Law Firm

Johnson & Johnson Talc Lawsuits Move to New Jersey

U.S. Bankruptcy Judge Craig Whitley in Charlotte, North Carolina ordered that tens of thousands of lawsuits against Johnson & Johnson be moved to New Jersey, according to a November 10, 2021 report from Reuters. Judge Whitley explained that his decision hinged on two factors: the fact that Johnson & Johnson is headquartered in New Jersey and the fact that a substantial amount of the country’s talc litigation is happening there.

read more

Philips' CPAP Repair Plan Could Take A Year to Wrap Up

Philips’ quarterly report offers encouraging words that the company’s CPAP repair and replacement program is “underway.” Some users will have to wait up to a year to benefit from the plan, the report continues.

The company further informs that it has produced around 750,000 replacement devices and repair kits. More than 250,000 are actually in consumers’ hands.

The delay in receiving new devices has been a point of frustration for users.

read more

How the J & J Bankruptcy Could Affect Talc Cancer Lawsuits

Plaintiffs in talc cancer lawsuits against Johnson & Johnson have had a white-knuckle time of it after hearing the company’s plans to file bankruptcy. If you are among the worriers, you should know that your legal action remains alive and well. However, J&J’s maneuverings could change some aspects of how your case is handled.

read more

Superior Court Judge Sets Dates for First U.S. Zantac Trials

Superior Court Judge Evelio Grillo for the County of Alameda, who oversees the California Ranitidine Product Cases Judicial Council Coordinated Proceedings (JCCP), has set a trial date of October 10, 2022, for the first cancer case trial. Drug makers Sanofi, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Chattem will move forward as defendants. Although the JCCP functions similarly to a federal multidistrict litigation (MDL), these cases are adjudicated within the California state court system.

read more

Lawsuits Filed for CION Investment Corp. (CIC) Investment Losses

The Levin Papantonio Rafferty law firm currently represents customers in claims to recover their investment losses in CION Investment Corp. On Tuesday, October 5, the shares of CION Investment Corp. began trading on the New York Stock Exchange under the ticker “CION.” Unfortunately for investors, shares closed trading on October 5 at $11.85 – representing a loss of over 40% of the principal for investors who purchased shares of CION at $10/share (shares underwent a reverse share split in September, resulting in an approximate halving of investors shares).

read more

FDA Requires New Warnings for Xeljanz and Other Arthritis Medicines Due to Heart Risks

The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) regarding the arthritis and ulcerative colitis drug Xeljanz (and Xeljanz XR), otherwise known as tofacitinib. After studying the results of a large, randomized safety clinical trial of the medicine, the agency stated there was evidence of “serious heart-related events,” including heart attack, stroke, cancer, blood clots, and death.

read more

Claims Filed Regarding Former Sarasota Financial Advisor Marc Korsch for Sale of Allegedly Speculative and High-Risk REITs and Illiquid Investments to Retirees

The Levin Papantonio Rafferty law firm announced today that it has filed claims on behalf of retiree investors who are former clients of Sarasota-area Financial Advisor Marc Korsch and NAV Advisors. According to his FINRA Brokercheck report, Mr. Korsch’s securities registration terminated last week on Friday, September 3 – which may leave clients stuck with illiquid investments that they cannot sell.

read more

The Parking REIT (MVP REIT II) – Investment Loss Recovery

Parking REIT investors may have suffered losses of over 75% of their investment principal, based on recent tender offers of less than $6.00 per share made by MacKenzie Capital Management.  Furthermore, data from limited secondary trading data sources shows a sale in June 2020 for amounts as low as $5.01 per share. The Parking REIT’s board estimated the share value at $11.75 as recently as June 2021, but even if that share value estimated was correct investors who paid $25.00 per share may have lost over 50% of their investment principal.

read more

Atlas Growth Partners LP Red Flags – Investors May Be Entitled to Recover Losses

Atlas Growth Partners LP was a high risk limited partnership dedicated to developing and producing natural gas, crude oil and NGLs. Based on Atlas Growth Partner’s SEC Filings, investors who were sold Atlas Growth Partners may have lost almost 99% of their investment principal. Atlas Growth Partners recently disclosed in a filing with the SEC that there were “significant risks and uncertainties related to our inability to satisfy our current liabilities raise substantial doubt about our ability to continue as a going concern.

read more

Philips CPAP Recall - Degradation of Foam Could Cause Cancer and Other Health Risks

Phillips Respironics has issued a voluntary recall of around 4 million CPAP and BiLevel PAP devices. According to the manufacturer’s notification, the company’s quality management system revealed these products pose serious health risks and potentially life-threatening injuries for users.

The first-generation DreamStation product family comprises the Philips medical devices most affected by the recall.

read more